Literature DB >> 17426456

The ever expanding role for c-Myc in promoting genomic instability.

Edward V Prochownik1, Youjun Li.   

Abstract

Genomic instability (GI) is a hallmark of many cancers. GI is believed to confer upon impending neoplastic cells the ability to accumulate all of the requisite mutations for transformation within the relatively short time-frame of an organism's lifespan. Recently described properties of the c-Myc oncoprotein show that, in addition to its directly transforming role, it can mediate GI via the induction of reactive oxygen species and by promoting whole chromosome instability leading to tetraploidy and aneuploidy. Mediators of both properties have been identified and have begun to provide a framework within which to understand not only how c-Myc alters the genome but how it might also cooperate with its more traditional transforming activities. These genome-altering properties of c-Myc suggest that they provide the protein with the ability to confer a "mutator phenotype" to cells in which its expression is deregulated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426456     DOI: 10.4161/cc.6.9.4161

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  34 in total

1.  Upregulated expression of Mina53 in cholangiocarcinoma and its clinical significance.

Authors:  Xiao-Ping Tan; Qing Zhang; Wei-Guo Dong; Xia-Wen Lei; Zi-Rong Yang
Journal:  Oncol Lett       Date:  2012-02-28       Impact factor: 2.967

Review 2.  Signal transduction in cancer.

Authors:  Richard Sever; Joan S Brugge
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

3.  Myc: the beauty and the beast.

Authors:  Amanda R Wasylishen; Linda Z Penn
Journal:  Genes Cancer       Date:  2010-06

4.  c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Richard E Clark
Journal:  Haematologica       Date:  2015-02-06       Impact factor: 9.941

Review 5.  Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming.

Authors:  I K Rony; A Baten; J A Bloomfield; M E Islam; M M Billah; K D Islam
Journal:  Cell Prolif       Date:  2015-01-29       Impact factor: 6.831

Review 6.  Multiple oncogenic roles of nuclear beta-catenin.

Authors:  Raju Kumar; Murali D Bashyam
Journal:  J Biosci       Date:  2017-12       Impact factor: 1.826

7.  Clinical implication of 14-3-3 epsilon expression in gastric cancer.

Authors:  Mariana Ferreira Leal; Danielle Queiroz Calcagno; Sâmia Demachki; Paulo Pimentel Assumpção; Roger Chammas; Rommel Rodríguez Burbano; Marília de Arruda Cardoso Smith
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

8.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

9.  MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel.

Authors:  Giuliana Gatti; Giovanna Maresca; Manuela Natoli; Fulvio Florenzano; Angelo Nicolin; Armando Felsani; Igea D'Agnano
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

10.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.

Authors:  Frank Westermann; Daniel Muth; Axel Benner; Tobias Bauer; Kai-Oliver Henrich; André Oberthuer; Benedikt Brors; Tim Beissbarth; Jo Vandesompele; Filip Pattyn; Barbara Hero; Rainer König; Matthias Fischer; Manfred Schwab
Journal:  Genome Biol       Date:  2008-10-13       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.